Document Type

Article

Publication Date

7-2020

Identifier

DOI: 10.1111/cts.12753; PMCID: PMC7359940

Abstract

Ranitidine has been the topic of recent media reports. Current findings, confirmed by the US Food and Drug Administration, indicate that some ranitidine products contain a substance that may be carcinogenic. Providers and patients require additional information on the risks of continuing therapy vs. the benefits of the medication. This article comments on what is currently known about the evolving situation of elevated N-nitrosodimethylamine levels in ranitidine and the limits of the existing information to assess best practices.

Journal Title

Clin Transl Sci

Volume

13

Issue

4

First Page

649

Last Page

651

Comments

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Download

Share

COinS